

87. The polypeptide according to Claim 78, wherein said polypeptide is unglycosylated.

88. A pharmaceutical composition comprising the polypeptide according to one of Claims 78 to 87 and a pharmaceutically acceptable carrier.--


REMARKS

Claims 44-77 are pending. Applicants herewith add new claims 78-88. Thus, with the entry of this amendment, claims 44-88 will be active in this case. Support for conservative substitutions can be found in the original specification at page 71, line 15 to page 72, line 8, where applicants discuss the similarity of the core region of the KGF molecule to the same region in other fibroblast growth factor family members. Thus, no new matter is added with these new claims. Examiner Saoud has previously indicated that applicants' claims encompass conservative amino acid substitutes.

Applicants believe the above claims are allowable and look forward to discussing the same at an interview to be arranged according to mutual convenience.

January 29, 1999
Date

Respectfully submitted,


Patricia D. Granados
Reg. No. 33,683

FOLEY & LARDNER
3000 K STREET, N.W.
SUITE 500
WASHINGTON, DC 20007
202-672-5477